|

Natural Killer Cell Therapy Clinical Trials

3 actively recruiting trials across 1 location

Pipeline

Early 1: 1Phase 1: 1Phase 1/2: 1

Top Sponsors

  • Kirsten Johnson1
  • Kari Kendra1
  • John Reneau1

Indications

  • Cancer3
  • Skin Nodular Basal Cell Carcinoma1
  • Skin Squamous Cell Carcinoma1
  • Skin Basal Cell Carcinoma1
  • Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma1

Columbus, Ohio3 trials

Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma

Ohio State University Comprehensive Cancer Center

Early 1
Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

Ohio State University Comprehensive Cancer Center

Phase 1/2
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.